A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)
Ramanan, A. V.
Dick, A. D.
Beresford, M. W.
- Publisher: BioMed Central
Safety | Rheumatology | Methotrexate | Study Protocol | Ophthalmology | Juvenile idiopathic arthritis | Uveitis | Adalimumab | Paediatric
mesheuropmc: skin and connective tissue diseases | genetic structures | musculoskeletal diseases
Background: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of inflammation of the uvea in the eye (uveitis). Overall, 20% to 25% of paediatric uveitis is associated with JIA. Major risk factors for dev...